Global Pet Inactivated Vaccine Market Research Report 2023

Publication ID:

PB509232739

Publication Date:

September 27, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Inactivated vaccines for pets are vaccines made from killed pathogens.
The global Pet Inactivated Vaccine market is projected to reach US$ 711.8 million in 2029, increasing from US$ 490.2 million in 2022, with the CAGR of 5.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pet Inactivated Vaccine 91制片厂.
According to Our PET Supplies Research Center, the global pet industry reached $ 261 billion in 2022, a year-on-year increase of 11.3%. The United States gains the highest pet penetration rate and becomes the largest pet market. According to the American Pet Products Association (APPA), 66% of American households keep pets, and the total industry sales was about US$136.8 billion, an increase of 10.8% over 2021. According to IVH, the German pet products industry association, the number of pets in Germany reached 33.4 million in 2022, with a total turnover of nearly 鈧�6.5 billion. The 2023 China Pet Industry Trend Insight White Paper released by JD shows that the market size of the four major pet physical commodities is increasing year by year: pet supplies account for 45%, pet staple food accounts for nearly 35%, pet snacks account for 12%, and pet medicine and health care account for 377%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Pet Inactivated Vaccine market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Bayer Healthcare
Vetoquinol S.A
Boehringer Ingelheim
Ceva
Eli Lilly
Heska
Merck Animal Health
Merial (Sanofi)
Virbac
Pfizer
Segment by Type
Obtained by Heat Killing
Killed by Chemical Methods such as Formaldehyde
Obtained by Radiation Killing
Segment by Application
Dog
Cat
Dird
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Pet Inactivated Vaccine report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers鈥� Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers鈥� Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Pet Inactivated Vaccine Market Overview
1.1 Product Overview and Scope of Pet Inactivated Vaccine
1.2 Pet Inactivated Vaccine Segment by Type
1.2.1 Global Pet Inactivated Vaccine Market Value Comparison by Type (2023-2029)
1.2.2 Obtained by Heat Killing
1.2.3 Killed by Chemical Methods such as Formaldehyde
1.2.4 Obtained by Radiation Killing
1.3 Pet Inactivated Vaccine Segment by Application
1.3.1 Global Pet Inactivated Vaccine Market Value by Application: (2023-2029)
1.3.2 Dog
1.3.3 Cat
1.3.4 Dird
1.3.5 Others
1.4 Global Pet Inactivated Vaccine Market Size Estimates and Forecasts
1.4.1 Global Pet Inactivated Vaccine Revenue 2018-2029
1.4.2 Global Pet Inactivated Vaccine Sales 2018-2029
1.4.3 Global Pet Inactivated Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Pet Inactivated Vaccine Market Competition by Manufacturers
2.1 Global Pet Inactivated Vaccine Sales Market Share by Manufacturers (2018-2023)
2.2 Global Pet Inactivated Vaccine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Pet Inactivated Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global Pet Inactivated Vaccine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Pet Inactivated Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pet Inactivated Vaccine, Product Type & Application
2.7 Pet Inactivated Vaccine Market Competitive Situation and Trends
2.7.1 Pet Inactivated Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pet Inactivated Vaccine Players Market Share by Revenue
2.7.3 Global Pet Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pet Inactivated Vaccine Retrospective Market Scenario by Region
3.1 Global Pet Inactivated Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Pet Inactivated Vaccine Global Pet Inactivated Vaccine Sales by Region: 2018-2029
3.2.1 Global Pet Inactivated Vaccine Sales by Region: 2018-2023
3.2.2 Global Pet Inactivated Vaccine Sales by Region: 2024-2029
3.3 Global Pet Inactivated Vaccine Global Pet Inactivated Vaccine Revenue by Region: 2018-2029
3.3.1 Global Pet Inactivated Vaccine Revenue by Region: 2018-2023
3.3.2 Global Pet Inactivated Vaccine Revenue by Region: 2024-2029
3.4 North America Pet Inactivated Vaccine Market Facts & Figures by Country
3.4.1 North America Pet Inactivated Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Pet Inactivated Vaccine Sales by Country (2018-2029)
3.4.3 North America Pet Inactivated Vaccine Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Pet Inactivated Vaccine Market Facts & Figures by Country
3.5.1 Europe Pet Inactivated Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Pet Inactivated Vaccine Sales by Country (2018-2029)
3.5.3 Europe Pet Inactivated Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pet Inactivated Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Pet Inactivated Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Pet Inactivated Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Pet Inactivated Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Pet Inactivated Vaccine Market Facts & Figures by Country
3.7.1 Latin America Pet Inactivated Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Pet Inactivated Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Pet Inactivated Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pet Inactivated Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Pet Inactivated Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Pet Inactivated Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Pet Inactivated Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Pet Inactivated Vaccine Sales by Type (2018-2029)
4.1.1 Global Pet Inactivated Vaccine Sales by Type (2018-2023)
4.1.2 Global Pet Inactivated Vaccine Sales by Type (2024-2029)
4.1.3 Global Pet Inactivated Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Pet Inactivated Vaccine Revenue by Type (2018-2029)
4.2.1 Global Pet Inactivated Vaccine Revenue by Type (2018-2023)
4.2.2 Global Pet Inactivated Vaccine Revenue by Type (2024-2029)
4.2.3 Global Pet Inactivated Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Pet Inactivated Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global Pet Inactivated Vaccine Sales by Application (2018-2029)
5.1.1 Global Pet Inactivated Vaccine Sales by Application (2018-2023)
5.1.2 Global Pet Inactivated Vaccine Sales by Application (2024-2029)
5.1.3 Global Pet Inactivated Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Pet Inactivated Vaccine Revenue by Application (2018-2029)
5.2.1 Global Pet Inactivated Vaccine Revenue by Application (2018-2023)
5.2.2 Global Pet Inactivated Vaccine Revenue by Application (2024-2029)
5.2.3 Global Pet Inactivated Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Pet Inactivated Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Bayer Healthcare
6.1.1 Bayer Healthcare Corporation Information
6.1.2 Bayer Healthcare Description and Business Overview
6.1.3 Bayer Healthcare Pet Inactivated Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Bayer Healthcare Pet Inactivated Vaccine Product Portfolio
6.1.5 Bayer Healthcare Recent Developments/Updates
6.2 Vetoquinol S.A
6.2.1 Vetoquinol S.A Corporation Information
6.2.2 Vetoquinol S.A Description and Business Overview
6.2.3 Vetoquinol S.A Pet Inactivated Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Vetoquinol S.A Pet Inactivated Vaccine Product Portfolio
6.2.5 Vetoquinol S.A Recent Developments/Updates
6.3 Boehringer Ingelheim
6.3.1 Boehringer Ingelheim Corporation Information
6.3.2 Boehringer Ingelheim Description and Business Overview
6.3.3 Boehringer Ingelheim Pet Inactivated Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Boehringer Ingelheim Pet Inactivated Vaccine Product Portfolio
6.3.5 Boehringer Ingelheim Recent Developments/Updates
6.4 Ceva
6.4.1 Ceva Corporation Information
6.4.2 Ceva Description and Business Overview
6.4.3 Ceva Pet Inactivated Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Ceva Pet Inactivated Vaccine Product Portfolio
6.4.5 Ceva Recent Developments/Updates
6.5 Eli Lilly
6.5.1 Eli Lilly Corporation Information
6.5.2 Eli Lilly Description and Business Overview
6.5.3 Eli Lilly Pet Inactivated Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Eli Lilly Pet Inactivated Vaccine Product Portfolio
6.5.5 Eli Lilly Recent Developments/Updates
6.6 Heska
6.6.1 Heska Corporation Information
6.6.2 Heska Description and Business Overview
6.6.3 Heska Pet Inactivated Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Heska Pet Inactivated Vaccine Product Portfolio
6.6.5 Heska Recent Developments/Updates
6.7 Merck Animal Health
6.6.1 Merck Animal Health Corporation Information
6.6.2 Merck Animal Health Description and Business Overview
6.6.3 Merck Animal Health Pet Inactivated Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Merck Animal Health Pet Inactivated Vaccine Product Portfolio
6.7.5 Merck Animal Health Recent Developments/Updates
6.8 Merial (Sanofi)
6.8.1 Merial (Sanofi) Corporation Information
6.8.2 Merial (Sanofi) Description and Business Overview
6.8.3 Merial (Sanofi) Pet Inactivated Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Merial (Sanofi) Pet Inactivated Vaccine Product Portfolio
6.8.5 Merial (Sanofi) Recent Developments/Updates
6.9 Virbac
6.9.1 Virbac Corporation Information
6.9.2 Virbac Description and Business Overview
6.9.3 Virbac Pet Inactivated Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Virbac Pet Inactivated Vaccine Product Portfolio
6.9.5 Virbac Recent Developments/Updates
6.10 Pfizer
6.10.1 Pfizer Corporation Information
6.10.2 Pfizer Description and Business Overview
6.10.3 Pfizer Pet Inactivated Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Pfizer Pet Inactivated Vaccine Product Portfolio
6.10.5 Pfizer Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pet Inactivated Vaccine Industry Chain Analysis
7.2 Pet Inactivated Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pet Inactivated Vaccine Production Mode & Process
7.4 Pet Inactivated Vaccine Sales and Marketing
7.4.1 Pet Inactivated Vaccine Sales Channels
7.4.2 Pet Inactivated Vaccine Distributors
7.5 Pet Inactivated Vaccine Customers
8 Pet Inactivated Vaccine Market Dynamics
8.1 Pet Inactivated Vaccine Industry Trends
8.2 Pet Inactivated Vaccine Market Drivers
8.3 Pet Inactivated Vaccine Market Challenges
8.4 Pet Inactivated Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Bayer Healthcare
Vetoquinol S.A
Boehringer Ingelheim
Ceva
Eli Lilly
Heska
Merck Animal Health
Merial (Sanofi)
Virbac
Pfizer

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.